Mental or Behavioral Dysfunction – Page 8

FDA Approves Tris Pharma’s Onyda XR, First Liquid Non-Stimulant ADHD Medication for Pediatric Patients ###

11 months ago talkbio0Tagged Approved, Attention deficit hyperactivity disorder, clonidine, Extended Release Suspension, hydrochloride, Liquid medication, LiquiXR, Non-stimulant, Onyda, Pediatric brand name, Svalbard, Technology, Tris Pharma, United States Food and Drug Administration

Tris Pharma, Onyda XR, ADHD, Non-stimulant, Liquid medication, Pediatric patients, FDA approval, Clonidine hydrochloride, Extended-release oral suspension, LiquiXR technology

Johnson & Johnson’s Seltorexant Achieves Significant Improvement in Depressive Symptoms and Sleep Disturbance in Phase 3 Trial

11 months ago talkbio0Tagged Johnson and Johnson, Major Depressive Disorder, Mental Depression, Neuroscience discipline, Phase 3 trial, Seltorexant, Sleeplessness, Symptoms aspect

Johnson & Johnson, Seltorexant, Major Depressive Disorder, Insomnia Symptoms, Phase 3 Trial, Neuroscience, Depression Treatment

AbbVie and Gilgamesh Pharmaceuticals Join Forces in a $2 Billion Psychedelic Drug Development Partnership

12 months ago talkbio0Tagged AbbVie, Drug Development, Gilgamesh, Hallucinogens, Mental disorders, mental health, Neuroscience discipline, next-generation

AbbVie, Gilgamesh Pharmaceuticals, psychiatric disorders, psychedelic drugs, drug development, mental health, next-generation treatments, neuroscience, pharmaceutical collaboration, $2 billion deal.

Takeda Pharmaceuticals Revises Profit Forecast Due to Vyvanse Patent Expiration, Plans $900M Restructuring by 2024

12 months ago talkbio0Tagged Attention deficit hyperactivity disorder, Expiration, function, Legal patent, profit, restructuring, Takeda, Vyvanse

Takeda Pharmaceuticals, Vyvanse, patent expiration, profit outlook, restructuring, ADHD medication

Uzedy, Teva, and MedinCell’s Collaborative Effort Yields Success in Phase 3 Trials for Long-Acting Schizophrenia Treatment

12 months ago talkbio0Tagged Collaboration, Injectables, long-acting, Medincell, mental health, Neuroscience discipline, Phase 3 trials, Psychiatry Specialty, Schizophrenia, Teva, Uzedy

Uzedy, Teva, MedinCell, long-acting, schizophrenia, phase 3 trials, treatment, collaboration, mental health, neuroscience, psychiatry, injectable medication.